Predicted protein targets (top 18)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 7/20 | 0.55 |
| ▸ | GAA | P10253 | 1/20 | 0.55 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.55 |
| ▸ | MAPT | P10636 | 3/20 | 0.50 |
| ▸ | NR4A2 | P43354 | 2/20 | 0.49 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.49 |
| ▸ | MEN1 | O00255 | 2/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.45 |
| ▸ | CYP1A2 | P05177 | 1/20 | 0.45 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.45 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.45 |
| ▸ | ROCK2 | O75116 | 1/20 | 0.45 |
| ▸ | LMNA | P02545 | 1/20 | 0.44 |
| ▸ | CHRNB2 | P17787 | 1/20 | 0.44 |
| ▸ | CHRNA4 | P43681 | 1/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3927071 | 0.92 | ALDH1A1 (0.49) | KDM4EGAAMAPK1MAPTALDH1A1 | |
| SCHEMBL11756564 | 0.83 | KDM4E (0.64) | KDM4EGAAMAPK1MAPTALDH1A1 | |
| SCHEMBL5449802 | 0.81 | CYP1A2 (0.55) | KDM4EGAAMAPTALDH1A1MEN1 | |
| SCHEMBL18773703 | 0.81 | KDM4E (0.64) | KDM4EGAAMAPK1MAPTNR4A2 | |
| SCHEMBL363534 | 0.81 | MAPT (0.66) | KDM4EGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL8391101 | 0.80 | KDM4E (0.55) | KDM4EGAAMAPK1MAPTNR4A2 | |
| SCHEMBL15545676 | 0.80 | HTR7 (0.51) | KDM4EGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL3787403 | 0.79 | MAPT (0.58) | KDM4EGAAMAPTALDH1A1SMN1; SMN2 | |
| SCHEMBL360551 | 0.79 | HTR2C (0.52) | KDM4EGAAMAPK1MAPTALDH1A1 | |
| SCHEMBL29684402 | 0.79 | HTR2C (0.52) | KDM4EGAAMAPK1MAPTALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 25 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2948453-B1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| EP-2948453-B1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS AG (CH) | 2017-08-02 | — | — | EP | disclosed |
| US-9556180-B2 | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-9556180-B2 | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| US-9556180-B2 | Pyrazolo[3,4-d]pyrimidinone compounds as inhibitors of the P53/MDM2 interaction | NOVARTIS AG (CH) | 2017-01-31 | — | — | US | disclosed |
| EP-2785717-B1 | PYRAZOLOPYRROLIDINE COMPOUNDS | NOVARTIS AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| EP-2785717-B1 | PYRAZOLOPYRROLIDINE COMPOUNDS | NOVARTIS AG (CH) | 2016-01-13 | — | — | EP | disclosed |
| US-20150353563-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS PHARMA AG (CH) | 2015-12-10 | — | — | US | disclosed |
| US-20150353563-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS PHARMA AG (CH) | 2015-12-10 | — | — | US | disclosed |
| US-20150353563-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS PHARMA AG (CH) | 2015-12-10 | — | — | US | disclosed |
| US-20140350010-A1 | Pyrazolopyrrolidine Compounds | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| US-20140350010-A1 | Pyrazolopyrrolidine Compounds | NOVARTIS AG (CH) | 2014-11-27 | — | — | US | disclosed |
| EP-2785717-A1 | PYRAZOLOPYRROLIDINE COMPOUNDS | Novartis AG (CH) | 2014-10-08 | — | — | EP | disclosed |
| WO-2014115080-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS AG (CH) | 2014-07-31 | — | — | WO | disclosed |
| WO-2014115080-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | NOVARTIS AG (CH) | 2014-07-31 | — | — | WO | disclosed |
| WO-2013080141-A1 | Pyrazolopyrrolidine compounds | NOVARTIS AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| WO-2013080141-A1 | Pyrazolopyrrolidine compounds | NOVARTIS AG (CH) | 2013-06-06 | — | — | WO | disclosed |
| US-7202244-B2 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2007-04-10 | — | — | US | disclosed |
| US-20040014765-A1 | Chk-1 inhibitors | MILLENNIUM PHARMACEUTICALS, INC. | 2004-01-22 | — | — | US | disclosed |
| WO-2003101444-A1 | DIARYLUREA COMPOUNDS AND DERIVATIVES AS CHK-1 INHIBITORS FOR THE TREATMENT OF CANCER | MILLENNIUM PHARMACEUTICALS, INC. (US) | 2003-12-11 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20140350010-A1 | Pyrazolopyrrolidine Compounds | MDM4, MDM2, TP53 | KDM4E 2322/4885GAA 379/4885MAPK1 971/4885 |
| US-20040014765-A1 | Chk-1 inhibitors | CHKA, CHKB, CHEK1 | KDM4E 1251/4885GAA 2750/4885MAPK1 245/4885 |
| US-20150353563-A1 | PYRAZOLO[3,4-D]PYRIMIDINONE COMPOUNDS AS INHIBITORS OF THE P53/MDM2 INTERACTION | TP53, MDM4, MDM2 | KDM4E 2728/4885GAA 1716/4885MAPK1 1050/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.